Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $56.28 USD
Change Today -1.27 / -2.21%
Volume 506.6K
PCRX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

pacira pharmaceuticals inc (PCRX) Key Developments

Pacira Pharmaceuticals, Inc. Reports Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Pacira Pharmaceuticals, Inc. reported consolidated unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $59,148,000 compared with $47,165,000 for the same period last year. Income from operations was $1,818, 000 compared with loss from operations of $2,842,000 for the same period last year. Income before income taxes was $47,000 compared with loss before income taxes of $5,037,000 for the same period last year. Net income was $8,000 or $0.00 basic and diluted per share compared with net loss of $5,037,000 or $0.14 basic and diluted per share for the same period last year. Non-GAAP net income was $8,379, 000 or $0.20 basic and diluted per share compared with non-GAAP net income of $1,535,000 or $0.04 basic and diluted per share for the same period last year. For the six months, the company reported total revenues of $117,463,000 compared with $83,828,000 for the same period last year. Income from operations was $5,158,000 compared with loss from operations of $12,099,000 for the same period last year. Income before income taxes was $1,359,000 compared with loss before income taxes of $16,514,000 for the same period last year. Net income was $1,268,000 or $0.03 basic and diluted per share compared with net loss of $16,514,000 or $0.48 basic and diluted per share for the same period last year. Non-GAAP net income was $18,190,000 or $0.44 basic and diluted per share compared with non-GAAP net income of $4,933,000 or $0.14 basic and diluted per share for the same period last year.

Pacira Pharmaceuticals, Inc. to Report Q2, 2015 Results on Jul 30, 2015

Pacira Pharmaceuticals, Inc. announced that they will report Q2, 2015 results at 9:00 AM, US Eastern Standard Time on Jul 30, 2015

Pacira Pharmaceuticals, Inc., Q2 2015 Earnings Call, Jul 30, 2015

Pacira Pharmaceuticals, Inc., Q2 2015 Earnings Call, Jul 30, 2015

Pacira Pharmaceuticals, Inc. Appoints Scott Braunstein as Senior Vice President to Oversee Strategy and Corporate Development

Pacira Pharmaceuticals, Inc. announced the appointment of Scott Braunstein, MD, to the newly created position of senior vice president, strategy and corporate development. He will be responsible for evaluating, integrating and optimizing the company’s strategic opportunities for the lead commercial product EXPAREL® (bupivacaine liposome injectable suspension); the company’s hospital-based sales franchise; the DepoFoam®-based internal pipeline product candidates; and external in-licensing and acquisition product candidates. Dr. Braunstein spent 12 years as a healthcare analyst and portfolio manager at J.P. Morgan Asset Management.

Pacira Pharmaceuticals, Inc. Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-11-2015 08:00 AM

Pacira Pharmaceuticals, Inc. Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-11-2015 08:00 AM. Venue: Le Parker Meridian, 119 West 56th Street, New York, NY 10019, United States. Speakers: David M. Stack, Chairman, Chief Executive Officer and President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PCRX:US $56.28 USD -1.27

PCRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $38.61 USD -1.18
Alkermes PLC $59.41 USD -0.15
Cumberland Pharmaceuticals Inc $6.08 USD +0.06
Durect Corp $2.06 USD 0.00
Halyard Health Inc $30.04 USD -1.40
View Industry Companies
 

Industry Analysis

PCRX

Industry Average

Valuation PCRX Industry Range
Price/Earnings 100.0x
Price/Sales 9.1x
Price/Book 10.8x
Price/Cash Flow 518.7x
TEV/Sales 8.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PACIRA PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.